Cancer Therapy Advisor

The Cancer Therapy Advisor is a free online platform that provides oncology healthcare experts with a diverse knowledge base of practical oncology data and clinical tools to assist in making the right choice for their patients.
Cancer Therapy Advisor avails practice-focused clinical and drug data that reflects present and emerging principles of care that will assist in informing oncology choices.

The Cancer Therapy Advisor offers a comprehensive range of authoritative publications and services for the professional medical community.

Key features:

Monthly Prescribing Reference (MPR).
Its Specialty editions.
Oncology Nurse Advisor.
For nurse practitioners and physician assistants.
Clinical Advisor.
Renal and Urology News.
Endocrinology Advisor.
Neurology Advisor.
Psychiatry Advisor.
Infectious Disease Advisor.
Medical Bag.
Rheumatology Advisor.
The Cardiology Advisor.
Clinical Pain Advisor.
Dermatology Advisor, a.
Pulmonology Advisor.

Who Needs the Cancer Therapy Advisor

Patients treated with neoadjuvant immune checkpoint inhibitor (ICI) based therapy for hepatocellular carcinoma (HCC) possesses a higher disease feature and achieves results comparable to HCC clients who go through the surgical process.
The research published in Cancer Research Communications assessed 92 patients who undertook clinical resection for HCC. Moreover, 56 other patients underwent upfront resection and 36 patients had neoadjuvant ICI-based medical procedures.

The Results

The research established that 62 per cent of the patients who had neoadjuvant therapy were not by the standard respectability criteria. Nevertheless, 94.4% of patients in this group underwent R0 resection. Moreover, there is a noteworthy variation of the 87.5% of clients who had R0 resection with open surgery (P =.474).
The data outcome highlights that the patients who had neoadjuvant ICI-based therapy were more likely to have results connected to higher-risk illness. Moreover, there is an inclusive α-fetoprotein ≥ 400 ng/mL at baseline (38.9% vs 14.3%; P =.02), tumors larger than 5 cm (72.2% vs 37.5%; P =.001), portal vein invasion (25.0% vs 0%; P <.001), and multiple tumor foci (50.0% vs 12.5%; P <.001).
The median recurrence-free survival was 44.8 months in the ICI-treated cohort and 49.3 months in the upfront surgery cohort (P =.66). The median overall survival was not reached in either cohort (P =.97).